News & Events

Second Medical Use – Novelty of New Mechanism of Action

  A newly discovered mode of action for a known compound can support patentable second medical use claims in Europe, even when the condition being treated is already known. This …

Read article

Protecting Wearable Technology

  Wearable technology spans different technologies, and protecting IP in this exciting and fast-moving space requires a strategic multi-faceted approach. This video highlights how to protect various aspects of wearables, …

Read article

Lack of Unity

  This video explains how the European Patent Office assesses unity of invention and the opportunities it provides to pay further search fees. It highlights the strategic importance of paying …

Read article

Drafting for the EPO

  The EPO adopts strict rules on added subject-matter, and has a number of unique formalities. This video briefly explores some key points for drafting patent applications for the EPO, …

Read article

Welcome to HGF Presents – New Video Series

Introducing HGF Presents a new video series delivering practical insights into European Patent Law and practice. Curated by our leading experts in chemistry, life sciences, technology & engineering, each concise …

Read article

Providing Enabling Disclosure for AI inventions at the EPO

  Video overview: The equivalent to the enablement requirement in the US at the EPO is Sufficiency. There is an increasing trend for the sufficiency of AI related patent applications …

Read article

Personalised Medicine Patenting of Known Drugs for Known Indications at the EPO

Video overview: The identification of specific sub-groups of patients to treat with a known drug, even if said patients may have been treated before with the drug, can yield patentable …

Read article

Novelty Over Clinical Trials at the EPO

Video overview: Second medical use claims can be novel over clinical trials in European patents. Typically, such a claim would be fairly narrow, e.g. perhaps mapping onto specific indications and …

Read article

Regulatory Exclusivity for
Medicinal Products in Europe

Video overview: New Medical Products 8 years of data exclusivity, followed by 2 years of market exclusivity. +1 year market exclusivity possible for a new indication showing significant clinical benefit. No exclusivity granted for new formulations or routes of …

Read article